Summary AM-Pharma BV (AM-Pharma) is a biopharmaceutical company that undertakes the preclinical and clinical development of recombinant human alkaline phosphatase therapeutics for the treatment of inflammatory diseases. The company offers products in the form of bovine alkaline phosphatase for treating diseases such as acute kidney injury and inflammatory bowel diseases. AM-Pharma’s products are also used to treat two major types of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. It develops products based on endogenous proteins and protein derived peptides, and other molecules that naturally occur in the human body. AM-Pharma is headquartered in Bunnik, the Netherlands. Am-Pharma BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types,... Research Beam Model: Research Beam Product ID: 2637706 250 USD New
Am-Pharma BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Am-Pharma BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : October   2017
  • Pages : 21
  • Publisher : GlobalData
 
 
 
Summary

AM-Pharma BV (AM-Pharma) is a biopharmaceutical company that undertakes the preclinical and clinical development of recombinant human alkaline phosphatase therapeutics for the treatment of inflammatory diseases. The company offers products in the form of bovine alkaline phosphatase for treating diseases such as acute kidney injury and inflammatory bowel diseases. AM-Pharma’s products are also used to treat two major types of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. It develops products based on endogenous proteins and protein derived peptides, and other molecules that naturally occur in the human body. AM-Pharma is headquartered in Bunnik, the Netherlands.

Am-Pharma BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Am-Pharma BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Am-Pharma BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 10
AM-Pharma Secures US$39.7 Million In Series D Financing 12
Acquisition 14
Pfizer Acquires Minority Stake in AM-Pharma 14
Am-Pharma BV - Key Competitors 15
Am-Pharma BV - Key Employees 16
Am-Pharma BV - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Clinical Trials 18
May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial 18
Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury 19
Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design” 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
Am-Pharma BV, Pharmaceuticals & Healthcare, Key Facts 2
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Am-Pharma BV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Am-Pharma BV, Deals By Therapy Area, 2011 to YTD 2017 8
Am-Pharma BV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 10
AM-Pharma Secures US$39.7 Million In Series D Financing 12
Pfizer Acquires Minority Stake in AM-Pharma 14
Am-Pharma BV, Key Competitors 15
Am-Pharma BV, Key Employees 16
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter